NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

A Phase Ib/II, Open-label Study of NBM-BMX as Monotherapy or in Combination With Radiotherapy and Temozolomide in Subjects With Solid Tumors or Newly Diagnosed Glioblastoma

NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.

Study Overview

• Status: Recruiting
• Conditions: Malignant Neoplasm; Malignant Neoplasm of Brain
• Intervention / Treatment: Drug: NBM-BMX Capsule; Drug: Temozolomide; Radiation: Standard radiotherapy

Detailed Description

This is a multi-center, open-label, 2-arm, phase Ib/II study to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in the treatment of solid tumors (Arm A) or in combination with radiotherapy/temozolomide in the treatment of glioblastoma (Arm B).

Arm A consists of dose escalation cohorts in subjects with advanced solid tumors who will be treated with NBM-BMX monotherapy at different dose levels. Arm B consists of dose escalation cohorts (Phase Ib) and expansion cohorts (Phase II) in subjects with newly diagnosed glioblastoma (GBM). Subjects will be treated with NBM-BMX at different dose levels in combination with the first-line standard of care treatment (i.e., concomitant Radiotherapy (RT)/TMZ followed by adjuvant TMZ) in Phase Ib. After the recommended Phase 2 dose (RP2D) is determined in Phase Ib, additional subjects will be enrolled and treated at the RP2D to evaluate the efficacy of NBM-BMX combination therapy.

• Study Type: Interventional
• Enrollment (Estimated): 79
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Chia-Chung Hou, Ph.D.; Phone Number: 101 +886 2 26559109; Email: alison.hou@novelwisepharma.com
• Study Contact Backup: Name: Karis Chiang; Phone Number: 506 +886 2 27891060; Email: karis.chiang@effpha.com

Study Locations

• Taiwan
  • Kaohsiung City, Taiwan, 807
    • Not yet recruiting
    • Kaohsiung Medical University Chung-Ho Memorial Hospital
    • Contact: Ann-Shung Lieu, M.D.; Phone Number: +886 7 3121101
  • Taichung, Taiwan, 407
    • Recruiting
    • Taichung Veterans General Hospital
    • Contact: Wen-Yu Cheng, M.D.; Phone Number: +886 4 23592525
  • Taipei, Taiwan, 112
    • Recruiting
    • Koo Foundation Sun Yat-Sen Cancer Center
    • Contact: Chi-Feng Chung, M.D.; Phone Number: +886 2 28970011
  • Taoyuan, Taiwan, 333
    • Recruiting
    • Linkou Chang-Gung Memorial Hospital
    • Contact: Kuo-Chen Wei, M.D.; Phone Number: +886 3 3281200

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Arm A (advanced solid tumors)

1. Having signed and dated the informed consent form.
2. Females or males > 18 years old.
3. Histologically or cytologically confirmed advanced solid tumors refractory to standard of care therapy, or for which no standard of care therapy is available.
4. Disease that is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Response Assessment in Neuro-Oncology (RANO) criteria (for CNS tumors).
5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

6. Adequate organ function as defined by the following criteria:

   1. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3 × upper limits of normal (ULN), unless liver metastases present, then ≤ 5 × ULN
   2. Total serum bilirubin ≤ 1.5 × ULN unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin ≤ 3 × ULN
   3. Absolute neutrophil count (ANC) ≥ 1,000/μL
   4. Platelets ≥ 75,000/μL
   5. Hemoglobin ≥ 8.0 g/dL
   6. Non-indexed estimated glomerular filtration rate (eGFR) ≥ 50 mL/min/1.73 m2 × BSA (m2)/1.73.

   Transfusion is not allowed to meet entry criteria.

7. QTcF ≤ 480 msec
8. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.

Arm B (newly diagnosed GBM)

1. Having signed and dated the informed consent form.
2. Females or males > 18 years old.
3. Newly diagnosed, histologically confirmed glioblastoma, non-resectable, partially resected or resected.
4. Karnofsky performance status (KPS) ≥ 60 at screening and before the initiation (Day 1) of concomitant therapy.
5. Disease that is measurable or evaluable as defined by Response Assessment in Neuro-Oncology (RANO) criteria.

6. Adequate organ function as defined by the following criteria:

   1. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3 × upper limit of normal (ULN), unless liver metastases present, then ≤ 5 × ULN
   2. Total serum bilirubin ≤ 1.5 × ULN unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin ≤ 3 × ULN
   3. Absolute neutrophil count (ANC) ≥ 1,500/μL
   4. Platelets ≥ 100,000/μL
   5. Hemoglobin ≥ 8.0 g/dL
   6. Non-indexed estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 × BSA (m2)/1.73.

   Transfusion is not allowed to meet entry criteria.

7. QTcF ≤ 480 msec
8. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.

Exclusion Criteria:

Arm A (advanced solid tumors)

1. Systemic anti-cancer treatment (investigational or approved) within 28 days or 5 half-lives of that drug (whichever is shorter) of the first dose of NBM-BMX.
2. Curative radiation therapy within 28 days or palliative RT within 7 days of the first dose of NBM-BMX.
3. Currently taking strong inhibitors (e.g., gemfibrozil) or inducers of CYP2C8.
4. Any of the following within 6 months of the first dose of NBM-BMX: pulmonary embolism events, deep vein thrombosis (DVT) events, myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack.
5. A positive test for hepatitis B (HBsAg) and/or hepatitis C (anti-HCV antibody), unless the HBV DNA level and/or HCV RNA level is below the limit of detection.
6. Known history of human immunodeficiency virus (HIV) infection.

7. Men and women of childbearing potential who are unwilling to use highly effective contraceptive methods during the study period.

   Highly effective contraceptive methods include implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, surgical sterilization or a partner who is sterile.

8. Females who are pregnant or breastfeeding.
9. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart, in the judgement of the investigator and/or sponsor, excess risks associated with study participation or study drug administration.

Arm B (newly diagnosed GBM)

1. Prior systemic therapy (including Gliadel wafer implant), immunotherapy, investigational agents, or radiotherapy for glioblastoma.
2. Currently taking strong inhibitors (e.g., gemfibrozil) or inducers of CYP2C8.
3. Corticosteroid use of > 8 mg/day dexamethasone or equivalent within 5 days before the first dose of NBM-BMX.
4. A history of hypersensitivity reaction to temozolomide or dacarbazine.
5. Any of the following within 6 months of the first dose of NBM-BMX: pulmonary embolism events, deep vein thrombosis (DVT) events, myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack.
6. A positive test for hepatitis B (HBsAg) and/or hepatitis C (anti-HCV antibody), unless the HBV DNA level and/or HCV RNA level is below the limit of detection.
7. Known history of human immunodeficiency virus (HIV) infection. Note: HIV testing is not required.

8. Men and women of childbearing potential who are unwilling to use highly effective contraceptive methods during the study period and for at least 6 months after the final dose of temozolomide.

   Highly effective contraceptive methods include implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, surgical sterilization or a partner who is sterile.

9. Female who are pregnant or breastfeeding.
10. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart, in the judgement of the investigator and/or sponsor, excess risks associated with study participation or study drug administration.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: monotherapy in advanced solid tumors; Subjects with advanced solid tumors will be treated with NBM-BMX monotherapy at different dose levels depending on the order of their enrollment.	Drug: NBM-BMX Capsule; Each capsule contains 100 mg of the active ingredient.
Experimental: combination therapy in newly diagnosed glioblastoma; Subjects with newly diagnosed glioblastoma will be treated with NBM-BMX at different dose levels in combination with the standard of care treatment (concomitant RT/TMZ followed by adjuvant TMZ). In the expansion study, Subjects will be treated with NBM-BMX at the recommended Phase 2 dose (RP2D) in combination with RT/TMZ.	Drug: NBM-BMX Capsule; Each capsule contains 100 mg of the active ingredient.; Drug: Temozolomide; TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.; Other Names: Temodal® Capsules; Radiation: Standard radiotherapy; A total dose of 60 Gy will be administered in 6 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
[Arm A, Phase Ib] Frequency of dose-limiting toxicity (DLT) at each dose level	To determine the maximum tolerated dose (MTD) for NBM-BMX monotherapy in subjects with advanced solid tumors, toxicities will be graded according to the National Cancer Institute Common Terminology.	up to 28 days
[Arm B, Phase Ib] Frequency of dose-limiting toxicity (DLT) at each dose level	To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for NBM-BMX in combination with RT and TMZ in subjects with newly diagnosed GBM, toxicities will be graded according to the National Cancer Institute Common Terminology.	up to 10 weeks
[Arm B, Phase II] Progression-free survival rate at 6 months (PFS6)	To assess the preliminary efficacy of NBM-BMX in combination with RT and TMZ in subjects with newly diagnosed GBM, the investigators will evaluate anti-tumor activity using RANO criteria.	up to 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency, types, severity, and relationship to NBM-BMX of adverse events (AEs)	The severity of AEs will be graded using NCI CTCAE Version 5.0 by the investigator.	up to 28 days
Preliminary assessment of anti-tumor activity by response evaluation criteria	Tumor response and progression will be assessed using the RECIST v1.1 or Response Assessment in Neuro-Oncology (RANO) criteria.	at least 8 weeks
Area under the plasma concentration versus time curve (AUC) of NBM-BMX	Blood samples will be collected at each pre-specified time point for measuring concentrations of NBM-BMX in plasma using a validated bioanalytical method.	Day 1, 8 and 15 for Cycle 1 only (each cycle is 28 days)
Peak plasma concentration (Cmax) of NBM-BMX	Blood samples will be collected at each pre-specified time point for measuring concentrations of NBM-BMX in plasma using a validated bioanalytical method.	Day 1, 8 and 15 for Cycle 1 only (each cycle is 28 days)
Time to maximum plasma concentration (Tmax) of NBM-BMX	Blood samples will be collected at each pre-specified time point for measuring concentrations of NBM-BMX in plasma using a validated bioanalytical method.	Day 1, 8 and 15 for Cycle 1 only (each cycle is 28 days)
Terminal elimination half-life (T1/2) of NBM-BMX	Blood samples will be collected at each pre-specified time point for measuring concentrations of NBM-BMX in plasma using a validated bioanalytical method.	Day 1, 8 and 15 for Cycle 1 only (each cycle is 28 days)

Collaborators and Investigators

• Sponsor: Novelwise Pharmaceutical Corporation

Study record dates

Study Major Dates

• Study Start (Actual): August 11, 2023
• Primary Completion (Estimated): May 30, 2028
• Study Completion (Estimated): September 30, 2029

Study Registration Dates

• First Submitted: August 11, 2023
• First Submitted That Met QC Criteria: August 22, 2023
• First Posted (Actual): August 25, 2023

Study Record Updates

• Last Update Posted (Actual): April 29, 2026
• Last Update Submitted That Met QC Criteria: April 24, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms by Site; Nervous System Neoplasms; Central Nervous System Neoplasms; Neoplasms; Brain Neoplasms; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Azoles; Dacarbazine; Triazenes; Imidazoles; Temozolomide
• Other Study ID Numbers: NBM-BMX-003

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No